The sales in the global opioid-induced respiratory depression market are expected to rise at a robust CAGR during the forecast period 2022-2032. Increasing research and development activities for developing novel diagnoses and therapeutics solutions for the treatment of respiratory depression is estimated to create growth prospects for the global opioid-induced respiratory depression market.
The instigation of opioid receptors in brainstem respiratory centers on the surface of the neuron results in opioid-induced respiratory depression. The group of interneurons in the ventral respiratory group of the brainstem medulla is called the pre-Bötzinger complex (preBötC).
The parabrachial nucleus or preBötC both are the cause of the respiratory pattern generation and expression of opioid receptors. The combination use of opioids with other centrally depressant drugs or opioid overdose leads to irregular breathing causing opioid-induced respiratory depression.
Over the past couple of years, a substantial rise in prevalence of opioid use and drug overdose is being witnessed across the globe, owing to the increasing availability and misuse use to treatment drugs, fueling the demand for associated diagnosis and treatment solutions.
For instance, according to a study published by the World Health Organization (WHO), approximately 62 million people worldwide were reported to be using opioids, out of which around 36.3 million people suffered from drug use disorder in the years 2019. The study also states that nearly 0.5 million deaths were caused due to drug use globally.
Devices such as pulse oximeter, audiometry, acoustic monitor, radar monitor, bioimpedance device, inductance plethysmograph, and others are extensively used for the diagnosis and treatment of opioid-induced respiratory depression, caused by drug use. Hence, growing burden of this disease is estimated to create high revenue generation opportunities in the global market.
Although there are numerous benefits associated with the use of opioid-induced respiratory depression solutions, extravagant initial cost, high cost of diagnosis & treatment, and need for qualified professionals are some of the factors impeding the sales in the market.
In addition to this, the presence of stringent regulatory approval policies and standards across countries such as the U.S., Germany, the U.K., and India among others for new medical product launches is restraining the growth in the global opioid-induced respiratory depression market.
As per FMI, North America is anticipated to emerge as a highly remunerative market for opioid-induced respiratory depression during the forecast period 2022-2032.
Opioids are strong analgesics that are used for the treatment of numerous diseases and relieving pain such as codeine, hydromorphone, morphine, methadone, oxycodone, and others. These analgesics are increasingly being misused, due to increasing smoking activities and growing addiction.
In addition to this, removal of the ban on use of marijuana in countries such as Canada has resulted in a significant surge in the prevalence of fatal opioid-related disorders such as opioid-induced respiratory depression. Hence, numerous players are increasingly focusing on research and development activities for the introduction of accurate diagnosis and reliable treatment solutions for aforementioned disease. This is projected to favor the growth of the opioid-induced respiratory depression market in North America.
Future Market Insights reveals that Western Europe is expected to account for a significant share in the global opioid-induced respiratory depression market from 2022 to 2032.
Due to the growing awareness regarding the ill effects of opioid use and increasing rehabilitation activities across Europe, there is a robust surge in the demand for opioid-induced respiratory depression solutions. Hence, key manufacturers in the market are emphasizing on launching novel therapeutics solutions to cater to growing demand.
For instance, in 2021, Sandoz, a Swiss-based manufacturer of generic and biosimilar medicines announced introducing an authorized generic Nasal Spray, Narcan® (naloxone hydrochloride), which can be used to reverse the opioid overdose for the treatment of opioid-related disorders such as opioid-induced respiratory depression. A slew of such new product launches is estimated to bolster the demand in the Western Europe market.
Some of the leading players in the opioid-induced respiratory depression market are Medtronic plc, Smiths Group, Masimo Corporation, Nihon Kohden Corporation, Covidien, GE Healthcare, Welch Allyn, Becton, Dickinson and Company, BioMed Jena GmbH, Hill-Rom, Inc., Natus Medical Incorporated, and others.
The market for opioid-induced respiratory depression is highly competitive, due to the large presence of market players, increasing new product launches, and adoption of collaboration, agreement, and acquisition strategies.
| Report Attribute | Details |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Countries Covered |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product Type:
By End User:
By Region:
FMI projects the sales of opioid-induced respiratory depression in the market is expected to rise at swift value CAGR by 2032
The global opioid-induced respiratory depression market is expected to be dominated by North America the forecast period 2022-2032.
Medtronic plc, Smiths Group, Masimo Corporation, Nihon Kohden Corporation, Covidien, GE Healthcare, Welch Allyn, Becton, Dickinson and Company, BioMed Jena GmbH, Hill-Rom, Inc., Natus Medical Incorporated, and others are some of the leading players in the prominent opioid-induced respiratory depression market.
Explore Similar Insights
Opioid-Induced Respiratory Depression Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
